Skip to main content
Contact Us
Back to Homepage
follow us on linkedin
follow us on facebook
follow us on twitter
follow us on youtube
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Site Search
toggle main menu
News
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Normal
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
12/13/2017
Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index
10/31/2017
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results
09/21/2017
Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
09/19/2017
Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares
09/15/2017
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09/14/2017
Marinus Pharmaceuticals Announces Public Offering of Common Stock
09/11/2017
Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone
08/01/2017
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results
06/29/2017
FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder
06/27/2017
Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression
05/02/2017
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results
05/01/2017
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results
04/18/2017
Marinus to present Ganaxolone DATA at American academy of neurology annual meeting
04/11/2017
Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer
03/13/2017
Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results
03/07/2017
Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results
02/14/2017
Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
01/27/2017
Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
01/05/2017
Marinus Provides Business Outlook for 2017
01/03/2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome